Table 1.
Baseline demographics, clinical characteristics, and chemotherapy information for patients with lymphoma at the Mayo Clinic prescribed HDMTX
| Characteristic | Patients (N = 80) |
|---|---|
| Age (years), median (IQR) | 68.6 (59.3–75.9) |
| Patients aged 65 years or older, n (%) | 51 (64) |
| Male, n (%) | 54 (68) |
| Caucasian, n (%) | 74 (93) |
| Weight (kg), median (IQR) | 80.5 (69.7–92.3) |
| BSA (m2), median (IQR) | 1.97 (1.80–2.14) |
| Male | 2.04 (1.93–2.15) |
| Female | 1.77 (1.68–1.93) |
| Diagnosis, n (%) | |
| DLBCL | 44 (57) |
| Primary DLBCL of the CNS | 23 (30) |
| EBV positive DLBCL of the elderly | 6 (8) |
| Other | 7 (9) |
| Bone marrow involvement, n (%) | 10 (12.5) |
| Percent involvement, median (IQR) | 15 (9–35) |
| Kidney parameters at baseline | |
| History of chronic kidney disease, n (%) | 5 (6) |
| Serum creatinine (mg/dL) | 0.8 ± 0.4 |
| Cystatin C (mg/dL) | 1.1 ± 0.5 |
| Estimated kidney function (mL/min), median (IQR) | |
| Cockcroft-Gault eCrCl | 99 ± 46 |
| CKD-EPI eGFRcreatinine | 93 ± 27 |
| CKD-EPI eGFRcystatin C | 83 ± 26 |
| CKD-EPI eGFRcreatinine-cystatin C | 88 ± 24 |
| Albumin at baseline (g/dL), median (IQR) | 3.8 (3.5–4.2) |
| Chemotherapy regimen distribution, n (%) | |
| HDMTX 8 g/m2 with rituximab and temozolomide | 37 (46) |
| HDMTX 3.5 g/m2 in combination with R-CHOP | 29 (36) |
| HDMTX monotherapy | 14 (18) |
| Protocol-defined dose (g/m2), n (%) | |
| 8 | 37 (46) |
| 3.5 | 34 (43) |
| 1.5 | 9 (11) |
| Delivered dose (g), median (IQR) | 7.55 (4.83–11.25) |
| Prevention of CNS involvement | 4.85 (3.4–6.85) |
| Treatment of active CNS disease | 10.85 (7.8–13.5) |
| Disease burden, n (%) | |
| Systemic disease | 37 (46) |
| CNS disease | 30 (38) |
| Both | 13 (16) |
| MTX dose history | |
| First MTX dose, n (%) | 38 (48) |
| Second MTX dose, n (%) | 26 (32) |
| Beyond second MTX dose, n (%) | 16 (20) |
| Number of doses beyond second dose, median (IQR) | 4 (3, 9) |
BSA body surface area, CNS central nervous system, CKD EPI Chronic Kidney Disease Epidemiology Collaboration, DLBCL diffuse large B-cell lymphoma, EBV Epstein–Barr virus, eCrCl estimated creatinine clearance, eGFR estimated glomerular filtration rate, HDMTX high-dose methotrexate, IQR interquartile range, MTX methotrexate, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone